Related Experiment Videos
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
D F Stojdl1, B Lichty, S Knowles
1Ottawa Regional Cancer Centre Research Laboratories, 501, Smyth Road, Ottawa, ON, Canada.
Nature Medicine
|July 11, 2000
Summary
Vesicular stomatitis virus (VSV) selectively kills interferon-non-responsive tumor cells, offering a new strategy for cancer treatment. This oncolytic virus shows promise in reducing tumor burden in preclinical models.
Area of Science:
- Virology
- Immunology
- Oncology
Background:
- Interferons activate antiviral and anti-tumor responses via cell surface receptors.
- Cancer cells with interferon pathway mutations resist treatment but may have impaired antiviral defenses.
Purpose of the Study:
- To investigate the efficacy of vesicular stomatitis virus (VSV) against interferon-non-responsive tumor cells.
- To explore VSV as a potential oncolytic virus therapy for resistant cancers.
Main Methods:
- Utilized VSV, an enveloped RNA virus sensitive to interferon.
- Tested VSV replication and killing of human tumor cell lines in the presence of interferon.
- Administered VSV intratumorally in mice with human melanoma xenografts.
Main Results:
- VSV rapidly replicated in and selectively killed various human tumor cell lines resistant to interferon.
- Normal cells were protected by interferon, while tumor cells were susceptible to VSV.
- Intratumoral VSV injection reduced tumor burden in a melanoma xenograft model.
Conclusions:
- VSV demonstrates selective oncolytic activity against interferon-non-responsive cancer cells.
- VSV represents a promising replication-competent oncolytic virus for treating resistant tumors.
- This study presents a novel strategy for targeting cancers with compromised interferon pathways.